On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
FridayJun 30, 2017 2:12 pm

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) Announces Availability of Green Leaf Farms Rosin Products at Las Vegas Dispensary

Player’s Network, Inc. (OTCQB: PNTV) today announced the availability of its Green Leaf Farms rosin products at the Pisos Dispensary, located just a few miles from the Las Vegas Strip. “This day has been a long time coming. It marks both the end of prohibition and the true beginning of mass distribution for Green Leaf Farms products,” Mark Bradley, CEO of Player’s Network, stated in the news release. “Our products are now available at the Pisos Dispensary in Las Vegas, as well as in top notch dispensaries in Henderson. We are aggressively moving on the opportunities provided by this growing…

Continue Reading

FridayJun 30, 2017 1:19 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 30, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SPI 38.58% – News: Successfully completes grid connection project in Suqian, Jiangsu Province IHRT 10.00% – News: Partners with Roc Nation and JAY-Z for radio launch of JAY-Z's new album PTRC 5.78% – News: Participates in drilling of second exploration well in Kern County, California FSC 4.74% – News: Focus of Fifth Street Asset Management’s (NASDAQ: FSAM) strategic discussions BLIN 3.25% – News: Moves on momentum from recently being selected as a digital experience…

Continue Reading

FridayJun 30, 2017 1:19 pm

NetworkNewsBreaks – Aeterna Zentaris, Inc. (NASDAQ: AEZS) Resubmits NDA for Macrilen™ for the Evaluation of AGHD in Adults

Aeterna Zentaris (NASDAQ: AEZS) shares are higher after the company this morning said that is has resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Macrilen™ for the evaluation of growth hormone deficiency in adults (AGHD). The resubmission comes ahead of the company’s previously announced schedule, and the company anticipates an FDA review period of six months. “We anticipate successful FDA approval and, as a result, we continue to build our commercial organization and infrastructure in preparation for the earliest possible launch of Macrilen™. Our focus is to be prepared to launch…

Continue Reading

FridayJun 30, 2017 12:45 pm

NetworkNewsBreaks – ORHub, Inc. (ORHB) Driving Health Care Cost Reduction of Up to 40% with Value-Based Software

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) was featured in a recent case study evaluating the value of its innovative platform at the Hoag Orthopedic Institute (HOI). Among the highlights from the study, researchers found that, by leveraging Microsoft Azure intelligence and analytics, ORHub is capable of helping medical providers achieve cost efficiencies of as much as 40 percent while simultaneously driving closure of reimbursement gaps. The significance of these potential savings is reinforced when studying current health care expenditures in the U.S., which exceed $3 trillion annually and account for roughly 17 percent of GDP. ORHub’s research indicates…

Continue Reading

FridayJun 30, 2017 11:46 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Announces Appointment of Dr. Michael Shannon as Chief Medical Consultant

On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant. Shannon brings decades of health care experience to the ABcann team, including time in both the private and public sectors. Among Shannon’s career highlights, in 1996, he assumed responsibilities within Health Canada for re-organizing the Canadian blood system and the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. In 2000, he entered the private sector, simultaneously directing a phase III clinical trial in Canada, the United States and Great…

Continue Reading

FridayJun 30, 2017 11:01 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Featured in Benzinga Article Evaluating Potential of Cannabinoids in Treating Alzheimer’s

On Thursday, India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, was featured in an article on Benzinga titled ‘Marijuana Could Help Treat Alzheimer's: Here's How It Would Work’. The article notes that soon after discovering the pathway by which low-dose THC binds to amyloid beta plaques and prevents them from aggregating on neurons, the University of South Florida filed a patent for that mechanism. Notably, IGC announced on June 12 that it had acquired exclusive rights to this patent, titled ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease’,…

Continue Reading

ThursdayJun 29, 2017 3:28 pm

NetworkNewsBreaks – SinglePoint, Inc. (SING) Enters High-Volume Manufacturing Agreement with Premier Biomedical (BIEI)

Premier Biomedical, Inc. (OTCQB: BIEI), a research-based company focused on the discovery and development of medical treatments for a wide range of diseases, this morning announced that it has reached an agreement with specialized holding company SinglePoint, Inc. (OTC: SING) to manufacture Premier’s new-design CBD Hemp Oil Patch in high volume. “We have been working very hard on making acquisitions and inside sales to boost revenues,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “This new business will contribute significantly to our revenue goals.” Per the update, Premier’s CBD Hemp Oil Skin Patch is expected to be the…

Continue Reading

ThursdayJun 29, 2017 12:25 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 29, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CHFS 15.66% – News: Receives FDA IDE approval for FlexFlow® Aquapheresis System clinical study SMDM 12.43% – News: Posts 2017 fiscal year results USEG 10.77% – News: Amends existing credit agreement TROV 7.49% – News: Enters manufacturing agreement with NerPharMa for supply of PCM-075 for AML trial BLIN 7.26% – News: Selected as digital experience provider by national manufacturer of construction materials CAPR 6.32% – News: Presenting at the 2017 PPMD Annual Connect Conference…

Continue Reading

ThursdayJun 29, 2017 12:25 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Poised to Benefit from Significant Shifts in China’s Economy

China is rapidly gaining on the United States’ leading position as the world’s largest economy, and Moxian, Inc. (NASDAQ: MOXC) is poised to profit from the impending economic transition by leveraging a unique platform that converts online users to retail customers. “Today, China’s economy is the second-largest in the world and is likely to overtake the U.S. sometime this century. The country is in the process of transforming itself from a global center of low-tech manufacturing into a major hub of innovation and consumption … To capture the immense new opportunities in China’s changing consumer market, companies must become more…

Continue Reading

ThursdayJun 29, 2017 12:22 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (IMLFF) Poised to Benefit from Scientific Reviews Concerning Medical Efficacy of Cannabinoids

An increasing volume of research demonstrates the medical efficacy of cannabinoids to treat a variety of medical concerns. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems, currently has two potential blockbuster therapies in development that are undergoing scientific review. “With areas of research in dermatology, ocular indications, pain and inflammation, central nervous system disorders, and respiratory and metabolic diseases, InMed’s current pipeline is targeting unmet medical conditions utilizing disease-specific formulations. InMed’s INM-750 may become the first therapy to modulate disease activity…

Continue Reading

Contact us: 212.418.1217